Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer (2023)
Fonte: Pharmaceuticals. Unidade: IQ
Assuntos: NEOPLASIAS PROSTÁTICAS, CITOMETRIA DE FLUXO, HIDRÓLISE
ABNT
GARDANI, Carla Fernanda Furtado et al. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, v. 16, p. 1-17 art. 1619, 2023Tradução . . Disponível em: https://dx.doi.org/10.3390/ph16111619. Acesso em: 26 ago. 2024.APA
Gardani, C. F. F., Pedrazza, E. L., Paz, V. S., Zanirati, G. G., Costa, J. C. da, Andrejew, R., et al. (2023). Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer. Pharmaceuticals, 16, 1-17 art. 1619. doi:10.3390/ph16111619NLM
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 ago. 26 ] Available from: https://dx.doi.org/10.3390/ph16111619Vancouver
Gardani CFF, Pedrazza EL, Paz VS, Zanirati GG, Costa JC da, Andrejew R, Ulrich H, Scholl JN, Figueiró F, Rockenbach L, Morrone FB. Exploring CD39 and CD73 expression as potential biomarkers in prostate cancer [Internet]. Pharmaceuticals. 2023 ; 16 1-17 art. 1619.[citado 2024 ago. 26 ] Available from: https://dx.doi.org/10.3390/ph16111619